Oric Pharmaceuticals
ORIC
12.01
+0.03
+0.25%
Oric Pharmaceuticals
US · ORIC
#3089 by market cap
Listed 2020
12.01
+0.03
+0.25%
Live - 5344 symbols - heartbeat 281s ago
· 2026-10-08 07:00
Pre-market
11.51
-4.16%
After-hours
12.01
0.00%
- Market cap
- 1.24B
- P/E (TTM)i
- -9.24
- P/Bi
- 3.27
- EPSi
- -1.47
- Div yieldi
- 0.00%
- 52W posi
- 64%
Reader sentiment
Are you bullish or bearish on ORIC?
Anonymous reader poll. Unscientific, not investment advice.
Revenue annual, last 8 years
Income statement
| Line item | 2018 | 2019 | 2020 | 2021 | 2022 | 2023 | 2024 | 2025 |
|---|---|---|---|---|---|---|---|---|
| Revenue | -- | -- | -- | -- | -- | -- | -- | -- |
| Gross profit | -- | -- | -- | -- | -- | -- | -- | -- |
| Selling & admin expenses | 3.35M | 5.73M | 13.42M | 22.01M | 25.09M | 25.61M | 28.82M | 33.19M |
| Research & development | 19.03M | 22.84M | 35.92M | 56.86M | 61.68M | 85.17M | 114.07M | 109.82M |
| Operating profit | -22.37M | -28.57M | -49.34M | -78.87M | -86.77M | -110.78M | -142.90M | -143.00M |
| Pretax profit | -21.36M | -26.88M | -73.70M | -78.72M | -89.12M | -100.70M | -127.85M | -129.47M |
| Tax | -- | -- | -- | -- | -- | -- | -- | -- |
| Net profit | -21.36M | -26.88M | -73.70M | -78.72M | -89.12M | -100.70M | -127.85M | -129.47M |
| Basic EPS | -1 | -1 | -3 | -2 | -2 | -2 | -2 | -1 |
| Diluted EPS | -1.12 | -1.40 | -3.36 | -2.07 | -2.25 | -1.96 | -1.83 | -1.47 |
| Line item | 2025-03 | 2025-06 | 2025-09 | 2025-12 | 2026-03 | 2026-06 |
|---|---|---|---|---|---|---|
| Revenue | -- | -- | -- | -- | -- | -- |
| Gross profit | -- | -- | -- | -- | -- | -- |
| Selling & admin expenses | 8.08M | 8.52M | 7.90M | 8.70M | 8.18M | 9.00M |
| Research & development | 24.64M | 30.55M | 28.77M | 25.86M | 31.44M | 36.30M |
| Operating profit | -32.72M | -39.06M | -36.67M | -34.55M | -39.62M | -45.30M |
| Pretax profit | -30.02M | -36.36M | -32.59M | -30.51M | -35.77M | -41.49M |
| Tax | -- | -- | -- | -- | -- | -- |
| Net profit | -30.02M | -36.36M | -32.59M | -30.51M | -35.77M | -41.49M |
| Basic EPS | 0 | 0 | 0 | 0 | 0 | 0 |
| Diluted EPS | -0.42 | -0.47 | -0.33 | -0.30 | -0.34 | -0.38 |
Balance sheet
| Line item | 2018 | 2019 | 2020 | 2021 | 2022 | 2023 | 2024 | 2025 |
|---|---|---|---|---|---|---|---|---|
| Total current assets | 43.72M | 90.00M | 296.70M | 240.52M | 210.46M | 212.60M | 262.25M | 288.47M |
| Cash & ST investments | 42.64M | 89.16M | 293.60M | 236.98M | 206.27M | 208.19M | 255.96M | 281.49M |
| Inventory | -- | -- | -- | -- | -- | -- | -- | -- |
| Total assets | 46.73M | 94.09M | 299.00M | 298.64M | 247.18M | 252.01M | 274.14M | 408.89M |
| Total current liabilities | 2.60M | 5.35M | 9.00M | 15.15M | 15.39M | 20.46M | 24.85M | 20.42M |
| Short-term debt | -- | -- | -- | 1.93M | 2.66M | 2.75M | 3.18M | 3.33M |
| Long-term debt | -- | -- | -- | -- | -- | -- | -- | -- |
| Total liabilities | 111,160,000.00 | 184,177,000.00 | 9,221,000.00 | 25,666,000.00 | 24,827,000.00 | 27,919,000.00 | 31,020,000.00 | 24,528,000.00 |
| Total equity | -64.43M | -90.08M | 289.78M | 272.98M | 222.35M | 224.09M | 243.12M | 384.36M |
| Retained earnings | -65.81M | -92.69M | -166.39M | -245.11M | -334.23M | -434.93M | -562.77M | -692.24M |
| Line item | 2025-03 | 2025-06 | 2025-09 | 2025-12 | 2026-03 | 2026-06 |
|---|---|---|---|---|---|---|
| Total current assets | 211.43M | 291.12M | 295.59M | 288.47M | 290.23M | 273.70M |
| Cash & ST investments | 203.72M | 282.51M | 287.14M | 281.49M | 281.93M | 264.76M |
| Inventory | -- | -- | -- | -- | -- | -- |
| Total assets | 242.86M | 346.86M | 431.19M | 408.89M | 436.76M | 404.69M |
| Total current liabilities | 17.62M | 18.05M | 20.18M | 20.42M | 17.77M | 20.76M |
| Short-term debt | 3.21M | 3.27M | 3.30M | 3.33M | 3.30M | 3.33M |
| Long-term debt | -- | -- | -- | -- | -- | -- |
| Total liabilities | 23,120,000.00 | 22,862,000.00 | 24,273,000.00 | 24,528,000.00 | 21,205,000.00 | 23,429,000.00 |
| Total equity | 219.74M | 324.00M | 406.92M | 384.36M | 415.56M | 381.26M |
| Retained earnings | -592.80M | -629.15M | -661.74M | -692.24M | -728.01M | -769.50M |
Cash flow
| Line item | 2018 | 2019 | 2020 | 2021 | 2022 | 2023 | 2024 | 2025 |
|---|---|---|---|---|---|---|---|---|
| Operating cash flow | -20.68M | -23.53M | -45.27M | -59.54M | -75.14M | -85.69M | -112.66M | -110.97M |
| Depreciation & amortization | 903.00K | 1.03M | 970.00K | 897.00K | 966.00K | 1.03M | 1.11M | 1.22M |
| Free cash flow | -21.21M | -24.30M | -45.94M | -60.48M | -77.22M | -86.54M | -113.85M | -111.68M |
| Dividends paid | -- | -- | -- | -- | -- | -- | -- | -- |
| Stock buybacks / issuance | 0 | 0 | 271.31M | 50.00M | 25.00M | 85.00M | 125.00M | 244.37M |
| Ending cash balance | 42.64M | 89.16M | 78.45M | 226.47M | 67.31M | 23.88M | 59.90M | 46.16M |
| Line item | 2025-03 | 2025-06 | 2025-09 | 2025-12 | 2026-03 | 2026-06 |
|---|---|---|---|---|---|---|
| Operating cash flow | -32.53M | -30.84M | -25.11M | -22.48M | -32.44M | -31.61M |
| Depreciation & amortization | 302.00K | 310.00K | 288.00K | 320.00K | 270.00K | 264.00K |
| Free cash flow | -32.92M | -30.91M | -25.15M | -22.71M | -32.44M | -31.96M |
| Dividends paid | -- | -- | -- | -- | -- | -- |
| Stock buybacks / issuance | 0 | 133.93M | 110.44M | 0 | 60.88M | 0 |
| Ending cash balance | 49.83M | 76.36M | 50.16M | 46.16M | 56.89M | 37.97M |
Returns & efficiency
| Line item | 2018 | 2019 | 2020 | 2021 | 2022 | 2023 | 2024 | 2025 |
|---|---|---|---|---|---|---|---|---|
| ROE %i | -- | -228.33 | -39.02 | -27.98 | -35.99 | -45.11 | -54.73 | -41.27 |
| ROA %i | -45.71 | -38.18 | -37.50 | -26.34 | -32.66 | -40.34 | -48.60 | -37.91 |
| ROIC %i | -- | -240.19 | -39.18 | -27.83 | -36.71 | -44.57 | -54.04 | -40.84 |
| 5-year avg ROE %i | -- | -- | -- | -- | -- | -- | -47.52 | -41.01 |
| EBIT margin %i | -- | -- | -- | -- | -- | -- | -- | -- |
| FCF / sales %i | -- | -- | -- | -- | -- | -- | -- | -- |
| Current ratioi | 16.84 | 16.81 | 32.96 | 15.87 | 13.68 | 10.39 | 10.56 | 14.13 |
| Quick ratioi | 16.42 | 16.65 | 32.61 | 15.64 | 13.40 | 10.18 | 10.30 | 13.79 |
| Debt / assetsi | -- | -- | 0.00 | 0.64 | 1.08 | 1.09 | 1.16 | 0.81 |
| LT debt / equityi | -- | -- | -- | -- | -- | -- | -- | -- |
| Interest coveragei | -- | -- | -- | -- | -- | -- | -- | -- |
| Revenue CAGR (3Y) %i | -- | -- | -- | 0.00 | 0.00 | 0.00 | 0.00 | 0.00 |
| Net income CAGR (3Y) %i | -- | -- | -- | -- | -- | -- | -- | -- |
| FCF CAGR (3Y) %i | -- | -- | -- | -- | -- | -- | -- | -- |
| Line item | 2025-03 | 2025-06 | 2025-09 | 2025-12 | 2026-03 | 2026-06 |
|---|---|---|---|---|---|---|
| ROE %i | -48.45 | -43.82 | -39.73 | -41.27 | -42.57 | -39.80 |
| ROA %i | -44.76 | -40.62 | -36.90 | -37.91 | -39.79 | -37.35 |
| ROIC %i | -47.93 | -43.40 | -39.36 | -40.84 | -42.14 | -39.43 |
| 5-year avg ROE %i | -- | -- | -- | -- | -- | -- |
| EBIT margin %i | -- | -- | -- | -- | -- | -- |
| FCF / sales %i | -- | -- | -- | -- | -- | -- |
| Current ratioi | 12.00 | 16.13 | 14.65 | 14.13 | 16.33 | 13.19 |
| Quick ratioi | 11.56 | 15.65 | 14.23 | 13.79 | 15.86 | 12.76 |
| Debt / assetsi | 1.32 | 0.94 | 0.77 | 0.81 | 0.75 | 0.82 |
| LT debt / equityi | -- | -- | -- | -- | -- | -- |
| Interest coveragei | -- | -- | -- | -- | -- | -- |
| Revenue CAGR (3Y) %i | -- | -- | -- | -- | -- | -- |
| Net income CAGR (3Y) %i | -- | -- | -- | -- | -- | -- |
| FCF CAGR (3Y) %i | -- | -- | -- | -- | -- | -- |
Quote time 2026-10-08 07:00:26 · For reference only, not investment advice and not tailored to your situation.